[
    [
        {
            "time": "",
            "original_text": "贝达药业（300558.SZ）：在研新药BPI-43487临床试验获批",
            "features": {
                "keywords": [
                    "贝达药业",
                    "BPI-43487",
                    "临床试验",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业（300558.SZ）：在研新药BPI-43487临床试验获批",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：在研新药BPI-43487获得临床试验批准通知书",
            "features": {
                "keywords": [
                    "贝达药业",
                    "BPI-43487",
                    "临床试验",
                    "批准通知书"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：在研新药BPI-43487获得临床试验批准通知书",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：在研新药BPI-43487临床试验获批",
            "features": {
                "keywords": [
                    "贝达药业",
                    "BPI-43487",
                    "临床试验",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：在研新药BPI-43487临床试验获批",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "研发日报丨恒瑞氟唑帕利胶囊、海思科环泊酚注射液获批上市",
            "features": {
                "keywords": [
                    "恒瑞",
                    "氟唑帕利胶囊",
                    "海思科",
                    "环泊酚注射液",
                    "获批上市"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "研发日报丨恒瑞氟唑帕利胶囊、海思科环泊酚注射液获批上市",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "天风证券：创新药行业 十年十倍赛道下的巨头与新规",
            "features": {
                "keywords": [
                    "天风证券",
                    "创新药",
                    "十年十倍",
                    "赛道",
                    "巨头",
                    "新规"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天风证券：创新药行业 十年十倍赛道下的巨头与新规",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：2021医药“春季躁动”有望提前到来 关注医药消费投资机会",
            "features": {
                "keywords": [
                    "医药生物",
                    "周报",
                    "春季躁动",
                    "提前到来",
                    "医药消费",
                    "投资机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：2021医药“春季躁动”有望提前到来 关注医药消费投资机会",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 1,
                "Market_Scope": 10,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]